For this award, a single Health Equity Team must have at least two — and up to four — related research projects (each led by a separate principal investigator with a separate application) that share a well-defined theme and overall objective. The research projects should have the potential to improve our understanding of or have a positive impact on identified barriers to optimal health outcomes for all people with CF related to race and ethnicity, sexual orientation or gender, or socioeconomic status. The projects may be designed to:
- Test new hypotheses and/or new methods.
- Advance established results
Proposed projects may be designed using clinical (observational/interventional), translational, epidemiologic, and/or implementation science methodology.
Each investigator is expected to be a significant contributor and share the responsibility and authority for leading and directing the project. Given the wide-ranging nature of cystic fibrosis care, it is imperative that research teams should include a transdisciplinary assortment of investigators. It is strongly encouraged that each study team include at least one member with a strong track record of publishing in the health equity research field demonstrating established expertise in health equity research. Investigators are expected to be thought partners on the proposed work with each investigator carrying a nearly equal role in the conduct of the work, and being fundamental to the ability to address the overarching research objective(s).
The Health Equity Team Science Award should not be used to support multi-site studies where one principal investigator’s (PI) role is solely to support enrollment, provide samples or data, or serve in a consulting role (please see the Clinical Research Award or Clinical Pilot & Feasibility Award request for applications for these projects). We strongly encourage investigators to use this award mechanism to launch interdisciplinary collaborations.
The Health Equity Team Science Award will run once per year over the next two years being published in November 2022 and November 2023. Unsuccessful applications submitted for the 2022 funding cycle may be revised and resubmitted for the November 2023 cycle.
- Applicants must speak with program staff prior to submission to ensure the project design is in line with the goals of this request for application. Failure to do so will result in the administrative withdrawal of the proposal. Please email Program Officer Dara Riva at firstname.lastname@example.org.
- At least two but no more than four investigators may be included on a given project. Co-investigators may be at the same or different institutions.
- United States residents and applicants from outside the United States are welcome to apply.
- Applicants must be independent investigators. An independent investigator is an individual who is out of fellowship training and whose institution allows them to submit applications for research funding as a PI. Clinical fellows and postdoctoral fellows may not be listed as a lead PI on any project.
Areas of Encouragement
The Cystic Fibrosis Foundation regularly assesses its key research priorities to ensure we are on track to accomplish our mission to cure CF and to provide people with CF the opportunity to lead long lives. Applicants are encouraged to align submissions to these priorities to maximize their potential for being funded.
Policies and Guidelines
Please review the 2023 Policies and Guidelines for complete submission information.
All letters of intent and full applications for 2023 must be submitted online at awards.cff.org by 5 p.m. ET.
Full application: March 29, 2023
For More Information
Those who are interested in any funding programs offered by the Foundation may get further information, or discuss the potential relevance of their studies or research by contacting the Grants and Contracts Management and Administration Office at email@example.com.
Please Direct Inquiries to:
Cystic Fibrosis Foundation
4550 Montgomery Ave.
Suite 1100 N
Bethesda, MD 20814